NephroGenex, Inc. (NASDAQ: NRX) is a clinical-stage pharmaceutical company focused on developing therapeutics to treat kidney diseases caused by pathogenic oxidative chemistries. The company collaborates with experts in pathogenic oxidative chemistries to build a strong portfolio of intellectual property and new active drug candidates. The company’s product pipeline includes an oral formulation of Pyridorin, which is being developed as a chronic therapeutic agent to slow the progression of diabetic nephropathy. For more information, visit the company’s website at www.nephrogenex.com.

Noble Financial Capital Markets, an equity research driven, full-service, investment banking boutique, is hosting its tenth annual equity conference in Sandpiper Bay, FL. Attended by institutional investors from across North America, the event features more than 140 public company executive teams from a diverse range of industries. For more information, visit www.noble.missionir.com.